Resveratrol Cancer Research Results

RES, Resveratrol: Click to Expand ⟱
Features: polyphenol
Found in red grapes and products made with grapes.
Resveratrol is a polyphenol compound found in various plant species, including grapes, berries, and peanuts.
• Anti-inflammatory effects, Antioxidant effects:
- Antiplatelet aggregation for stroke prevention
- BioAvialability use piperine
- some sources may use Japanese knotweed roots (Reynoutria Japonica - root) as source which might contain Emodin (laxative)
-known as Nrf2 activator, both in cancer and normal cells. Which raises controversity of use in ROS↑ therapies. Interestingly there are reports of NRF2↑ and ROS↑ in cancer cells. This raises the question of if it is a chemosensitizer. However other reports indicate NRF2 droping with Res, indicating it maybe a chemosenstizer.
- RES is also considered to be them most effective natural SIRT1↑ -activating compound (STACs).

However, in the presence of certain metals, such as copper or iron, resveratrol can undergo a process called Fenton reaction, which can lead to the generation of reactive oxygen species (ROS). The pro-oxidant effects of resveratrol are often observed at high concentrations, typically above 50-100 μM, and in the presence of certain metals or other pro-oxidant agents. In contrast, the antioxidant effects of resveratrol are typically observed at lower concentrations, typically below 10-20 μM.

Clinical trials have used doses ranging from 150 mg to 5 grams per day. Lower doses (< 1 g/day) are often well-tolerated, but higher doses might be necessary for therapeutic effects and can be associated with side effects.

-Note half-life 1-3 hrs?.
BioAv poor: min 5uM/L required for chemopreventive effects, but 25mg Oral only yeilds 20nM. co-administration of piperine
Pathways:
- usually induce ROS production in cancer cells, while reducing ROS in normal cells.
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓,
- Lowers AntiOxidant defense in Cancer Cells: NRF2(typically increased), TrxR↓**, SOD↓, GSH↓ Catalase↓ HO1↓(wrong direction), GPx↓
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, TIMP2, IGF-1↓, uPA↓, VEGF↓, ROCK1↓, FAK↓, RhoA↓, NF-κB↓, CXCR4↓, SDF1↓, TGF-β↓, α-SMA↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, EZH2↓, P53↑, HSP↓, Sp proteins↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓, TOP1↓, TET1↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, PFKs↓, PDKs↓, ECAR↓, OXPHOS↓, GRP78↑, Glucose↓, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- inhibits Cancer Stem Cells : CSC↓, CK2↓, Hh↓, CD133↓, CD24↓, β-catenin↓, sox2↓, notch2↓, nestin↓, OCT4↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, ERK↓, JNK,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Rank Pathway / Axis Cancer Cells Normal Cells Label Primary Interpretation Notes
1 Reactive oxygen species (ROS) ↑ ROS (dose- & context-dependent) ↓ ROS / buffered Conditional Driver Biphasic redox modulation Resveratrol can act as a pro-oxidant in cancer cells while functioning as an antioxidant in normal cells
2 Mitochondrial integrity / intrinsic apoptosis ↓ ΔΨm; ↑ caspase activation ↔ preserved Driver Execution of intrinsic apoptosis Mitochondrial dysfunction and apoptosis follow ROS elevation in cancer cells
3 SIRT1 / AMPK axis ↑ AMPK; context-dependent SIRT1 modulation ↑ SIRT1 / ↑ AMPK Driver Metabolic stress signaling Resveratrol modulates energy-sensing pathways affecting survival and metabolism
4 PI3K → AKT → mTOR axis ↓ AKT / ↓ mTOR ↔ adaptive suppression Secondary Growth and anabolic inhibition Downregulation of growth signaling contributes to cytostasis and apoptosis sensitization
5 NF-κB signaling ↓ NF-κB activation ↓ inflammatory NF-κB tone Secondary Suppression of survival and inflammatory transcription NF-κB inhibition contributes to reduced proliferation and invasion
6 Cell cycle regulation ↑ G1/S or G2/M arrest ↔ largely spared Phenotypic Cytostatic growth control Cell-cycle arrest reflects upstream signaling disruption
7 HIF-1α / VEGF axis ↓ HIF-1α; ↓ VEGF ↔ minimal Secondary Anti-angiogenic pressure Interference with hypoxia-driven adaptation and angiogenesis


Scientific Papers found: Click to Expand⟱
3067- RES,    Proteomic Profiling Reveals That Resveratrol Inhibits HSP27 Expression and Sensitizes Breast Cancer Cells to Doxorubicin Therapy
- in-vitro, BC, MCF7
Apoptosis↑, MMP↓, Cyt‑c↑, Casp3↑, Casp9↑, HSP27↓,
3066- RES,    Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells
- in-vitro, Ovarian, NA
GSK‐3β↑, Akt↓, CHOP/DDIT3↑, ER Stress↑, PERK↑, ATF6↑, UPR↑, GlucoseCon↓,
3065- RES,    Resveratrol-induced cytotoxicity in human Burkitt's lymphoma cells is coupled to the unfolded protein response
- in-vitro, lymphoma, NA
UPR↑, IRE1↑, p‑eIF2α↑, PERK↑, ATF6↑, GRP78/BiP↑, GRP94↑, CHOP/DDIT3↑, GADD34↑, ATF4↑, XBP-1↑, Ca+2↑, ER Stress↑,
3064- RES,    Resveratrol Suppresses Cancer Cell Glucose Uptake by Targeting Reactive Oxygen Species–Mediated Hypoxia-Inducible Factor-1α Activation
- in-vitro, CRC, HT-29 - in-vitro, BC, T47D - in-vitro, Lung, LLC1
FDG↓, ROS↓, Hif1a↓, GLUT1↓, lactateProd↓,
3063- RES,    Resveratrol: A Review of Pre-clinical Studies for Human Cancer Prevention
- Review, Var, NA
*Inflam↓, *antiOx↑, *AntiAg↑, *chemoPv↑, ChemoSen↑, BioAv↑, Half-Life↝, COX2/PTGS2↓, cycD1/CCND1↓, CDK2↓, CDK4↓, CDK6↓, P21↑, MMP9↓, NF-kB↓, Telomerase↓, PSA↓, MAPK↑, P53↑,
3062- RES,    Resveratrol enhances post-injury muscle regeneration by regulating antioxidant and mitochondrial biogenesis
- in-vivo, Nor, NA
*antiOx↑, *Keap1↓, *NRF2↑, *HO-1↑, *GPx↑, *SOD↑,
3061- RES,    The Anticancer Effects of Resveratrol: Modulation of Transcription Factors
- Review, Var, NA
AhR↓, NRF2↑, *NQO1↑, *HO-1↑, *GSH↑, P53↑, Cyt‑c↑, Diablo↑, Bcl-2↓, Bcl-xL↓, survivin↓, XIAP↓, FOXO↑, p‑PI3K↓, p‑Akt↓, BIM↑, DR4↑, DR5↑, p27/CDKN1B↑, cycD1/CCND1↓, SIRT1↑, NF-kB↓, ATF3↑,
3060- RES,    Resveratrol targeting NRF2 disrupts the binding between KEAP1 and NRF2-DLG motif to ameliorate oxidative stress damage in mice pulmonary infection
- in-vitro, Nor, RAW264.7 - in-vivo, NA, NA
*NRF2↑, *antiOx↑, *ROS↓,
3059- RES,    Resveratrol, an Nrf2 activator, ameliorates aging-related progressive renal injury
- in-vivo, Nor, HK-2
*RenoP↑, *Inflam↓, *NRF2↑, *HO-1↑, *SIRT1↑, *ROS↓, AntiAge↑,
3058- RES,    Resveratrol inhibits estrogen-induced breast carcinogenesis through induction of NRF2-mediated protective pathways
- in-vivo, BC, NA
*NRF2↑,
3057- RES,    The therapeutic effect of resveratrol: Focusing on the Nrf2 signaling pathway
- Review, Var, NA - Review, AD, NA - Review, Stroke, NA
*NRF2↑, *Keap1↓, *ROS↓, *Apoptosis↓, *Inflam↓, *antiOx↑, *hepatoP↑, *neuroP↑, *cardioP↑, *RenoP↑, *AntiCan↑, *memory↑, *SOD↑, *GPx↑, *Catalase↑, *MDA↓, *NRF2↑, *HO-1↑, *ROS↓, *Aβ↓, *iNOS↓, *COX2/PTGS2↓, *GSH↑, *HO-1⇅, *SIRT1↑,
3798- RES,    Resveratrol reverses hippocampal synaptic markers injury and SIRT1 inhibition against developmental Pb exposure
- in-vivo, Nor, NA
*SIRT1↑, *BDNF↑, *PSD95↑, *memory↑,
101- RES,    Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis
- in-vitro, GC, SGC-7901
HH↓, Gli1↓, EMT↓, Snail↓, N-cadherin↓, E-cadherin↑, TumCI↓, TumMeta↓,
4663- RES,    Exploring resveratrol’s inhibitory potential on lung cancer stem cells: a scoping review of mechanistic pathways across cancer models
- Review, Var, NA
*antiOx↑, *Inflam↓, *chemoPv↑, CSCs↓, Wnt↓, β-catenin/ZEB1↓, NOTCH↓, PI3K↓, Akt↓, mTOR↓, GSK‐3β↝, Snail↓, HH↓, p‑GSK‐3β↓, N-cadherin↓, EMT↓, CD133↓, CD44↓, ALDH1A1↓, OCT4↓, SOX4↓, Shh↓, Smo↓, Gli1↓, GLI2↓,
4662- RES,    A Promising Resveratrol Analogue Suppresses CSCs in Non-Small-Cell Lung Cancer via Inhibition of the ErbB2 Signaling Pathway
- in-vitro, NSCLC, A549 - in-vitro, NSCLC, H460
CSCs↓, CD133↓, OCT4↓, β-catenin/ZEB1↓, HER2/EBBR2↓, TumCP↓, PI3K↓, Akt↓, ALDH1A1↓, eff↑,
4657- RES,    Resveratrol, cancer and cancer stem cells: A review on past to future
- Review, Var, NA
CSCs↓, CD133↓, Shh↓, Twist↓, Snail↓, MMP2↓, MMP9↓, Smad1↓, CD44↓, ALDH1A1↓, OCT4↓, Nanog↓, STAT3↓, survivin↓, cycD1/CCND1↓, COX2/PTGS2↓, cMyc↓,
4289- RES,    Resveratrol Attenuates Formaldehyde Induced Hyperphosphorylation of Tau Protein and Cytotoxicity in N2a Cells
- in-vitro, AD, NA
*antiOx↑, *p‑tau↓, *GSK‐3β↓, *CaMKII ↓, *PP2A↑, *neuroP↑,
4288- RES,    Trans-resveratrol Inhibits Tau Phosphorylation in the Brains of Control and Cadmium Chloride-Treated Rats by Activating PP2A and PI3K/Akt Induced-Inhibition of GSK3β
- in-vivo, AD, NA
*memory↑, *GSH↑, *ROS↓, *MDA↓, *p‑tau↓, *PI3K↑, *Akt↑, *AMPK↑, *PP2A↑, *GSK‐3β↓,
4287- RES,    Resveratrol targeting tau proteins, amyloid-beta aggregations, and their adverse effects: An updated review
- Review, AD, NA
*p‑tau↓,
4286- RES,    Neuroprotective Properties of Resveratrol and Its Derivatives—Influence on Potential Mechanisms Leading to the Development of Alzheimer’s Disease
- Review, AD, NA
*neuroP↑, *Inflam↓, *antiOx↑, *GSH↑, *HO-1↑, *iNOS↓, *BDNF↑, *p‑CREB↑, *PKA↑, *Bcl-2↑, *BAX↓, *IL1β↓, *IL6↓, *MMP9↓, *memory↑, *AMPK↑, *PGC-1α↓, *NF-kB↓, *Aβ↓, *SIRT1↑, *p‑tau↓, *PP2A↑, *lipid-P↓, *NLRP3↓, *BACE/β-secretase↓,
4285- RES,    Resveratrol Rescues Tau-Induced Cognitive Deficits and Neuropathology in a Mouse Model of Tauopathy
- in-vivo, AD, NA
*tau↓, *cognitive↑, *Inflam↓,
4284- RES,    Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex
- in-vitro, AD, HEK293 - NA, Stroke, NA - in-vivo, AD, NA
*p‑tau↓, *PP2A↑, *neuroP↑, *antiOx↑, COX2/PTGS2↓, *AntiAg↑, *SIRT1↑, *AMPK↑, *Acetyl-CoA↓, *FAO↑, *ADAM10↑, *BACE/β-secretase↓, *Aβ↓, *memory↑, *Inflam↓, *ROS↓,
4154- RES,    Resveratrol improves postnatal hippocampal neurogenesis and brain derived neurotrophic factor in prenatally stressed rats
- in-vivo, AD, NA
*neuroP↑, *BDNF↑,
4153- RES,    Effect of oral resveratrol on the BDNF gene expression in the hippocampus of the rat brain
- in-vivo, AD, NA
*neuroP↑, *BDNF↑,
3863- RES,  MLT,  VitA,RetA,    Target Enzymes Considered for the Treatment of Alzheimer's Disease and Parkinson's Disease
- Review, AD, NA - Review, Park, NA
*ADAM10↑, *ADAM10↑, *ADAM10↑,
102- RES,    Effect of resveratrol on proliferation and apoptosis of human pancreatic cancer MIA PaCa-2 cells may involve inhibition of the Hedgehog signaling pathway
- in-vitro, PC, MIA PaCa-2
HH↓, PTCH1↓, Smo↓, HH↓, EMT↓, PI3K/Akt↓, NF-kB↓, TumCP↓, Apoptosis↑, ChemoSen↑,
3858- RES,    Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer’s Disease Treatment
- Review, AD, NA
*neuroP↑, *antiOx↑, *LDL↓, *ADAM10↑,
3056- RES,    Less is more for cancer chemoprevention: evidence of a non-linear dose response for the protective effects of resveratrol in humans and mice
- in-vivo, Nor, NA
*AMPK↑, *P21↑, *Dose↓, *chemoPv↑,
103- RES,  CUR,  QC,    The effect of resveratrol, curcumin and quercetin combination on immuno-suppression of tumor microenvironment for breast tumor-bearing mice
- vitro+vivo, BC, 4T1
ROS↑, MMP↓, Bcl-2↓, BAX↑, Casp9↑, T-Cell↑, TGF-β↓,
3614- RES,    Resveratrol--a boon for treating Alzheimer's disease?
- Review, AD, NA
*SIRT1↑, *neuroP↑,
3613- RES,    Resveratrol for Alzheimer's disease
- Review, AD, NA
*SIRT1↑, *BioAv↝, *toxicity↓, *ROS↓, *antiOx↑, *Aβ↓, *MMP9↓, *TNF-α↓,
3612- RES,    Resveratrol in Alzheimer's disease: a review of pathophysiology and therapeutic potential
- Review, AD, NA
*other↑, *Aβ↓, *Inflam↓, *NF-kB↓, *neuroP↑, *HO-1↑, *lipid-P↓, *COX2/PTGS2↓, *AMPK↑, *Catalase↑, *SOD↑, *GSR↑, *ROS↓, *MMP9↓, *cognitive↑, *SIRT1↑, *IL1β↓, *IL6↓,
3100- RES,    Neuroprotective effects of resveratrol in Alzheimer disease pathology
- Review, AD, NA
*neuroP↑, *BioAv↓, *Half-Life↓, *BioAv↑, *BBB↑, *NRF2↑, *BioAv↓, *BioAv↑, *SIRT1↑, *cognitive↑, *lipid-P↓, *HO-1↑, *SOD↑, *GSH↑, *GPx↑, *G6PD↑, *PPARγ↑, *AMPK↑, *Aβ↓,
3099- RES,    Resveratrol and cognitive decline: a clinician perspective
- Review, Nor, NA - NA, AD, NA
*antiOx↑, *ROS↓, *cognitive↑, *neuroP↑, *SIRT1↑, *AMPK↑, *GPx↑, *HO-1↑, *GSK‐3β↑, *COX2/PTGS2↓, *PGE2↓, *NF-kB↓, *NO↓, *Casp3↓, *MMP3↓, *MMP9↓, *MMP↑, *GSH↑, *other↑, *BioAv↑, *memory↑, *GlutMet↑, *BioAv↓, *Half-Life↓, *toxicity∅,
3098- RES,    Regulation of Cell Signaling Pathways and miRNAs by Resveratrol in Different Cancers
- Review, Var, NA
NOTCH2↓, Wnt↓, β-catenin/ZEB1↓, p‑SMAD2↓, p‑SMAD3↓, PTCH1↓, Smo↓, Gli1↓, E-cadherin↑, NOTCH⇅, TAC?, NKG2D↑, DR4↑, survivin↓, DR5↑, BAX↑, p27/CDKN1B↑, cycD1/CCND1↓, Bcl-2↓, STAT3↓, STAT5↓, JAK↓, DNAdam↑, γH2AX↑,
3097- RES,    Resveratrol Induces Notch2-mediated Apoptosis and Suppression of Neuroendocrine Markers in Medullary Thyroid Cancer
- in-vitro, Thyroid, TT
TumCG↓, cl‑Casp3↑, p‑PARP↑, NOTCH2↑,
3096- RES,    Identification of potential target genes of non-small cell lung cancer in response to resveratrol treatment by bioinformatics analysis
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
TumCP↓, Apoptosis↑, Akt↓, mTOR↓, p38↑, MAPK↑, STAT3↓, ROS↑, SIRT1↑, SOX2↓,
3095- RES,    Resveratrol suppresses migration, invasion and stemness of human breast cancer cells by interfering with tumor-stromal cross-talk
- in-vitro, BC, NA
TumCP↓, TumCMig↓, TumCI↓, cycD1/CCND1↓, cMyc↓, MMP2↓, MMP9↓, SOX2↓, Akt↓, STAT3↓, α-SMA↓,
3094- RES,    Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
CSCs↓, tumCV↓, FASN↑, BNIP3↑, *cardioP↑, *antiOx↑, NF-kB↓, COX2/PTGS2↓, MMP9↓, IGF-1↓, ERK↓, lipid-P↓, CD24↓,
3093- RES,    Pro-Oxidant Effect of Resveratrol on Human Breast Cancer MCF-7 Cells is Associated with CK2 Inhibition
- in-vitro, BC, MCF7
ROS↑, CK2↓,
3092- RES,    Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action
- Review, BC, MDA-MB-231 - Review, BC, MCF7
TumCP↓, tumCV↓, TumCI↓, TumMeta↓, *antiOx↑, *cardioP↑, *Inflam↓, *neuroP↑, *Keap1↓, *NRF2↑, *ROS↓, p62↓, IL1β↓, CRP↓, VEGF↓, Bcl-2↓, MMP2↓, MMP9↓, FOXO4↓, POLD1↓, CK2↓, MMP↓, ROS↑, Apoptosis↑, TumCCA↑, Beclin-1/ATG6↓, Ki-67↓, ATP↓, GlutMet↓, PFK↓, TGF-β↓, SMAD2↓, SMAD3↓, Vim?, Snail↓, Slug↓, E-cadherin↑, EMT↓, Zeb1↓, Fibronectin↓, IGF-1↓, PI3K↓, Akt↓, HO-1↑, Synergy↑, PD-1↓, CD8+↑, Th1 response↑, CSCs↓, RadioS↑, SIRT1↑, Hif1a↓, mTOR↓,
3091- RES,    Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, Pca, ALVA-41
CK2↓, Apoptosis↑,
3090- RES,    The Effects of Resveratrol Targeting MicroRNA-4325P/PDGF-B to Regulate Tumor Angiogenesis in Osteosarcoma Microenvironment
- in-vitro, OS, MG63
PDGFR-BB↓, angioG↓,
1489- RES,    Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer
- Review, Var, NA
RadioS↑, ChemoSen↑, *BioAv↓, *BioAv↑, Ferroptosis↑, lipid-P↑, xCT/SLC7A11↓, GPx4↓, *BioAv↑, COX2/PTGS2↓, cycD1/CCND1↓, FasL↓, FOXP3↓, HLA↑, p‑NF-kB↓, BAX↑, Bcl-2↓, MALAT1↓,
877- RES,    Resveratrol Inhibits Invasion and Metastasis of Colorectal Cancer Cells via MALAT1 Mediated Wnt/β-Catenin Signal Pathway
- in-vitro, CRC, LoVo - in-vitro, CRC, HCT116
MALAT1↓, Wnt/(β-catenin)↓, TumCI↓, TumMeta↓,
2334- RES,    Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy
- Review, Var, NA
GLUT1↓, GlucoseCon↓, lactateProd↓, Akt↓, mTOR↓, Dose↝, SIRT6↑, PKM2↓, HK2↓, PFK1↓, ChemoSen↑,
2333- RES,    Resveratrol regulates insulin resistance to improve the glycolytic pathway by activating SIRT2 in PCOS granulosa cells
- in-vitro, Nor, NA
*glucose↓, *Insulin↓, *IGFR↓, *IGF-1↓, *LDHA↑, *HK2↑, *PKM2↑, *Glycolysis↝, *SIRT2↑,
2332- RES,    Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism
- Review, Var, NA
Glycolysis↓, GLUT1↓, PFK1↓, Hif1a↓, ROS↑, PDH↑, AMPK↑, TumCG↓, TumCI↓, TumCP↓, p‑NF-kB↓, SIRT1↑, SIRT3↑, LDH↓, PI3K↓, mTOR↓, PKM2↓, R5P↝, G6PD↓, TKT↝, talin↓, HK2↓, GRP78/BiP↑, GlucoseCon↓, ER Stress↑, Warburg↓, PFK↓,
2331- RES,    Resveratrol improves follicular development of PCOS rats via regulating glycolysis pathway and targeting SIRT1
- in-vivo, Nor, NA
*LDHA↑, *PKM2↑, *SIRT1↑, *Glycolysis↝,
2330- RES,    Resveratrol Induces Cancer Cell Apoptosis through MiR-326/PKM2-Mediated ER Stress and Mitochondrial Fission
- in-vitro, CRC, DLD1 - in-vitro, Cerv, HeLa - in-vitro, BC, MCF7
TumCP↓, Apoptosis↑, PKM2↓, ER Stress↑,

Showing Research Papers: 51 to 100 of 180
Prev Page 2 of 4 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 180

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↓, 1,   Catalase↑, 1,   GPx↑, 2,   GPx4↓, 1,   GSH↓, 1,   GSH↑, 2,   GSR↑, 1,   GSTs↑, 1,   H2O2↑, 1,   HO-1↓, 1,   HO-1↑, 3,   lipid-P↓, 2,   lipid-P↑, 1,   NRF2↓, 1,   NRF2↑, 8,   Prx↓, 1,   ROS↓, 4,   ROS↑, 28,   ROS⇅, 2,   ROS↝, 1,   mt-ROS↑, 1,   SOD↑, 3,   SOD2↓, 1,   TAC?, 1,   TAC↑, 1,   TKT↝, 1,   Trx↓, 1,   Trx1↓, 1,   xCT/SLC7A11↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MKP5↑, 1,   OCR↑, 1,   OXPHOS↓, 1,   OXPHOS↑, 1,   PDH↑, 2,   SIRT3↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

5LO↓, 1,   AMPK↑, 4,   ATP↓, 2,   ATP↑, 1,   CRM↑, 1,   ECAR↓, 1,   FASN↑, 1,   FBI-1↓, 1,   FDG↓, 1,   G6PD↓, 1,   glucose↓, 1,   GlucoseCon↓, 6,   glut↓, 1,   GlutMet↓, 1,   GlutMet↑, 1,   Glycolysis↓, 6,   GSK‐3β↑, 2,   GSK‐3β↝, 2,   p‑GSK‐3β↓, 1,   HK2↓, 6,   lactateProd↓, 7,   NADPH↑, 1,   PFK↓, 2,   PFK1↓, 2,   PKM2↓, 7,   PPP↓, 1,   R5P↝, 1,   SIRT1↓, 1,   SIRT1↑, 12,   SIRT2↓, 1,   TCA↑, 1,   Warburg↓, 2,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 19,   BAX↓, 1,   BAX↑, 7,   Bcl-2↓, 9,   Bcl-xL↓, 3,   BIM↑, 1,   BNIP3↑, 1,   Casp3↑, 8,   cl‑Casp3↑, 1,   Casp9↑, 4,   Cyt‑c↑, 4,   Diablo↑, 1,   DR5↑, 2,   FasL↓, 1,   Ferroptosis↑, 1,   iNOS↓, 1,   Mcl-1↓, 2,   MDM2↓, 1,   necrosis↑, 1,   p38↓, 1,   p38↑, 1,   p‑p38↑, 2,   PUMA↑, 1,   survivin↓, 8,   TumCD↑, 1,   XIAP↓, 2,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 15,   p‑Akt↓, 1,   CK2↓, 3,   EGFR↓, 4,   ERK↓, 3,   p‑ERK↓, 1,   HER2/EBBR2↓, 1,   IGF-1R↓, 1,   JAK↓, 1,   JAK2↓, 1,   p‑JNK↓, 2,   MAPK↓, 2,   MAPK↑, 2,   mTOR↓, 8,   PDGFR-BB↓, 1,   PI3K↓, 8,   p‑PI3K↓, 1,   PI3K/Akt↓, 1,   PTEN↑, 5,   RAS↓, 1,   Sp1/3/4↓, 8,   Sp1/3/4↑, 1,   Src↓, 1,   STAT3↓, 8,   p‑STAT3↓, 2,   STAT5↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF3↑, 1,   ATF4↑, 1,   cJun↑, 1,   cMyc↓, 7,   DNMTs↓, 2,   EZH2↓, 1,   FOXO↑, 2,   FOXO4↓, 1,   HDAC↓, 3,   HDAC1↓, 2,   HDAC3↓, 1,   HDAC8↓, 1,   miR-21↓, 1,   miR-27a-3p↓, 1,   OCT4↓, 4,   other↓, 3,   other↑, 1,   other↝, 2,   SOX2↓, 3,   SOX4↓, 1,   SOX9↑, 1,   tumCV↓, 6,   ZBTB10↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↑, 2,   CHOP/DDIT3↑, 4,   p‑eIF2α↑, 2,   ER Stress↑, 5,   GRP78/BiP↓, 1,   GRP78/BiP↑, 2,   GRP94↑, 1,   HSP27↓, 1,   IRE1↑, 1,   PERK↑, 2,   UPR↑, 2,   XBP-1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↓, 1,   p62↓, 2,   p62↑, 1,   TumAuto↓, 1,   TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1,   BRCA1↑, 1,   DNAdam↓, 1,   DNAdam↑, 3,   P53↑, 11,   p53 Wildtype∅, 1,   PARP↑, 1,   p‑PARP↑, 1,   cl‑PARP↑, 2,   cl‑PARP1↑, 1,   POLD1↓, 1,   RAD51↓, 1,   SIRT6↑, 1,   Telomerase↓, 1,   TOP1?, 1,   TOP2↓, 1,   TP53↑, 1,   γH2AX↑, 3,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 1,   CDK4↝, 1,   CDK6↓, 1,   cellSen↑, 1,   p‑CHK1↑, 1,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 9,   cycD1/CCND1↑, 1,   cycE/CCNE↑, 1,   GADD34↑, 1,   Ki-67↓, 4,   P21↓, 1,   P21↑, 5,   p27/CDKN1B↓, 1,   p27/CDKN1B↑, 5,   TumCCA↑, 13,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 2,   ALDH1A1↓, 4,   Axin2↓, 1,   BMP2↑, 1,   BMPs↑, 1,   CD133↓, 6,   CD24↓, 1,   CSCs↓, 15,   EP4/PTGER4↑, 1,   FGF↑, 1,   Gli1↓, 6,   HH↓, 7,   IGF-1↓, 2,   Ki-67↓, 4,   Nanog↓, 3,   Nestin↓, 1,   NOTCH↓, 3,   NOTCH⇅, 1,   NOTCH1↓, 1,   NOTCH2↓, 1,   NOTCH2↑, 1,   p300↓, 1,   PTCH1↓, 2,   Shh↓, 3,   Smo↓, 3,   TumCG↓, 9,   TumCP↓, 18,   Wnt↓, 8,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

ACTA2↓, 1,   Ca+2↓, 1,   Ca+2↑, 3,   Ca+2↝, 1,   E-cadherin↓, 2,   E-cadherin↑, 9,   EMT↓, 17,   FAK↓, 2,   Fibronectin↓, 1,   Fibronectin↑, 1,   GLI2↓, 1,   ITGB1↓, 1,   MALAT1↓, 3,   MMP13↓, 1,   MMP2↓, 8,   MMP3↓, 1,   MMP7↓, 2,   MMP9↓, 14,   MMPs↓, 5,   N-cadherin↓, 6,   N-cadherin↑, 1,   Rho↓, 1,   ROCK1↓, 2,   Slug↓, 3,   Smad1↓, 1,   SMAD2↓, 2,   p‑SMAD2↓, 1,   SMAD3↓, 2,   p‑SMAD3↓, 1,   Snail↓, 6,   Snail↑, 1,   talin↓, 1,   TET1↑, 2,   TGF-β↓, 3,   TIMP1↑, 2,   TIMP2↑, 2,   TIMP3↑, 1,   TumCI↓, 15,   TumCMig↓, 9,   TumMeta↓, 8,   Twist↓, 1,   TXNIP↑, 1,   uPA↓, 1,   uPAR↓, 1,   Vim?, 1,   Vim↓, 4,   Vim↑, 1,   Zeb1↓, 2,   α-SMA↓, 2,   β-catenin/ZEB1↓, 9,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 9,   HIF-1↓, 1,   Hif1a↓, 12,   Hif1a↑, 1,   VEGF↓, 11,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 4,   MMP↓, 8,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↓, 1,   CD44↓, 6,   CD8+↑, 1,   COX2/PTGS2↓, 13,   CXCL12↓, 1,   CXCR2↑, 1,   CXCR4↓, 2,   DR4↑, 2,   FOXP3↓, 1,   HLA↑, 1,   IL1↓, 1,   IL10↓, 1,   IL18↓, 1,   IL1β↓, 2,   IL6↓, 6,   IL8↓, 2,   Inflam↓, 3,   Macrophages↓, 1,   MCP1/CCL2↓, 1,   NAF1↓, 3,   Neut↓, 1,   NF-kB↓, 16,   p‑NF-kB↓, 2,   NLRP3↓, 5,   p65↓, 1,   PD-1↓, 1,   PD-L1↑, 1,   PGE2↓, 1,   PSA↓, 2,   T-Cell↓, 1,   T-Cell↑, 2,   TCF↓, 2,   Th1 response↑, 1,   TNF-α↓, 4,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AhR↓, 1,   AhR↑, 1,   AR↓, 4,   ER-α36↑, 1,   FGF21↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 5,   BioAv↑, 3,   BioAv↝, 1,   BioEnh?, 1,   ChemoSen↑, 17,   ChemoSen⇅, 1,   Dose?, 1,   Dose↑, 2,   Dose↝, 8,   eff↓, 4,   eff↑, 9,   eff↝, 3,   Half-Life↓, 1,   Half-Life↑, 1,   Half-Life↝, 3,   MDR1↓, 1,   P450↓, 1,   RadioS↑, 8,   selectivity↑, 1,   Synergy↑, 10,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 4,   BRCA1↑, 1,   CRP↓, 1,   E6↓, 1,   EGFR↓, 4,   EZH2↓, 1,   HER2/EBBR2↓, 1,   IL6↓, 6,   LDH↓, 1,   PD-L1↑, 1,   PSA↓, 2,   TP53↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   AntiCan↑, 1,   AntiTum↑, 4,   cardioP↑, 2,   chemoPv↑, 3,   ChemoSideEff↓, 1,   hepatoP↑, 1,   hepatoP↝, 1,   NKG2D↑, 1,   toxicity↓, 1,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 367

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 23,   ARE↝, 1,   Catalase↑, 7,   GPx↑, 5,   GSH↑, 9,   GSR↑, 2,   GSTs↑, 1,   H2O2↓, 1,   HO-1↑, 11,   HO-1⇅, 1,   Keap1↓, 3,   lipid-P↓, 7,   mt-lipid-P↓, 1,   MDA↓, 4,   MPO↓, 2,   NQO1↑, 3,   NRF2↑, 13,   NRF2↝, 1,   RNS↓, 1,   ROS↓, 31,   ROS↑, 1,   SOD↑, 7,   TAC↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

Mets↝, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

DRP1/DNM1L↓, 5,   DRP1/DNM1L↑, 1,   FIS1↓, 6,   FIS1↑, 1,   Insulin↓, 2,   MFN1↑, 2,   MFN2↓, 1,   MFN2↑, 4,   mtDam↓, 4,   OPA1↓, 1,   OPA1↑, 3,   PGC-1α↓, 1,   PGC-1α↑, 7,   SIRT3↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

Acetyl-CoA↓, 1,   ALAT↓, 2,   AMPK↑, 13,   ATP↑, 3,   CRM↑, 2,   ECAR∅, 1,   FAO↑, 1,   FASN↓, 1,   G6PD↑, 1,   glucose↓, 1,   GlutMet↑, 1,   Glycolysis↓, 1,   Glycolysis↝, 2,   GSK‐3β↓, 4,   GSK‐3β↑, 1,   HK2↑, 1,   LDHA↑, 2,   LDL↓, 1,   NAD↑, 1,   NADH:NAD↑, 1,   PDK1 / PDPK1↓, 1,   p‑PDK1 / PDPK1↓, 1,   PKM2↑, 2,   SIRT1↑, 24,   SIRT2↑, 1,   SREBP1/SREBF1↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 3,   BAX↓, 1,   Bcl-2↑, 1,   Casp3↓, 1,   Cyt‑c∅, 1,   iNOS↓, 2,   iNOS↑, 1,   p38↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 1,   Akt↑, 1,   p‑Akt↓, 1,   p‑Akt↑, 1,   CaMKII ↓, 1,   p‑CREB↑, 2,   ERK↓, 1,   IGFR↓, 1,   mTOR↓, 1,   PI3K↑, 2,   PKA↑, 1,   PKCδ↑, 1,   PP2A↑, 4,   PTEN↑, 1,   Sp1/3/4↓, 3,   Sp1/3/4↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

cMyc↑, 1,   FOXO↑, 2,   FOXO1↝, 1,   miR-155↓, 1,   miR-29b↑, 1,   other?, 3,   other↑, 4,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP70/HSPA5↝, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   p62↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CLOCK↝, 1,   IGF-1↓, 3,   IGFBP3↑, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 9,   MMP3↓, 1,   MMP9↓, 5,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↑, 1,   eNOS↑, 1,   Hif1a↓, 1,   NO↓, 2,   TXA2↑, 1,   VEGF↓, 1,   VEGF↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↓, 1,   BBB↑, 3,   GLUT1↓, 1,   MMP↑, 3,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 5,   IL1β↓, 4,   IL6↓, 2,   Inflam↓, 21,   NF-kB↓, 8,   NF-kB↑, 1,   p‑NF-kB↓, 1,   NLRP3↓, 4,   p65↓, 1,   PGE2↓, 1,   TLR4↓, 1,   TNF-α↓, 3,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 3,   ADAM10↑, 6,   BDNF↑, 4,   PSD95↑, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 13,   BACE/β-secretase↓, 3,   tau↓, 3,   p‑tau↓, 6,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

PPARγ↑, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 9,   BioAv↑, 12,   BioAv↝, 2,   BioAv∅, 1,   BioEnh↑, 1,   CompStab↑, 2,   DDS↑, 2,   Dose↓, 1,   Dose↑, 1,   Dose↝, 8,   eff↑, 6,   Half-Life↓, 2,   Half-Life↝, 1,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   AST↓, 1,   BP↓, 3,   IL6↓, 2,   TMAO↓, 4,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 6,   antiAll↑, 1,   AntiCan↑, 2,   cardioP↑, 8,   chemoPv↑, 3,   cognitive↑, 9,   hepatoP↑, 5,   memory↑, 8,   motorD↑, 4,   neuroP↑, 23,   OS↑, 2,   radioP↑, 1,   RenoP↑, 2,   Strength↓, 1,   toxicity↓, 3,   toxicity↑, 1,   toxicity∅, 1,   Weight↓, 1,   Weight↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

GutMicro↑, 2,  
Total Targets: 177

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:141  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page